|
|
EQSNews: PAION AG
/ Key words: Capital Increase
PAION AG to issue approximately 4.8 million shares at EUR 1.90 per share in capital increase with subscription rights
20.10.2023 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
... Lire le communiqué |
|
| |
|
| |
|
|
EQSAdhoc: PAION AG / Key words: Capital Increase
PAION AG to issue approximately 4.8 million shares in capital increase with subscription rights
19Oct2023 / 20:56 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation EU No 596/2014, transmitted by EQS News a service of EQS Group AG.
The issuer is solely r... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: PAION AG
/ Key words: Capital Increase
PAION AG announces fully underwritten rights issue with target gross proceeds of EUR 10 million
13.10.2023 / 13:06 CET/CEST
The issuer is solely responsible for the content of this announcement.
&... Lire le communiqué |
|
| |
|
| |
|
|
EQSAdhoc: PAION AG / Key words: Capital Increase
PAION AG announces fully underwritten rights issue with target gross proceeds of EUR 10 million
13Oct2023 / 12:57 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation EU No 596/2014, transmitted by EQS News a service of EQS Group AG.
The issuer is solely... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: PAION AG
/ Key words: Regulatory Admission
PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE MUNDIPHARMA IN JAPAN
28.09.2023 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
PAION ANNOUNCES SUBMISSIO... Lire le communiqué |
|
| |
|
| |
|
|
OriginalResearch: PAION AG von First Berlin Equity Research GmbH
Einstufung von First Berlin Equity Research GmbH zu PAION AG
Unternehmen: PAION AG
ISIN: DE000A0B65S3
Anlass der Studie: Update
Empfehlung: Buy
seit: 18.09.2023
Kursziel: €11.0
Kursziel auf Sicht von: 12 months
Letzte Ratingänderung:
Analyst: Simon Scholes
First Berlin Equity Research has... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: PAION AG
/ Key words: Regulatory Approval
PAION receives UK MHRA approval of Byfavo® remimazolam for the induction and maintenance of general anesthesia in adults
31.08.2023 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.... Lire le communiqué |
|
| |
|
| |
